Shenzhen Cell Valley team visited Ludaopei Medical Group for exchange
At the symposium, Chairman Shi Yuanyuan introduced the rapid development of Shenzhen Cell Valley in the past six months, as well as the achievements made in the innovation and development of cell products, the breakthrough of viral vector technology, the construction of auxiliary declaration platform, and the improvement of talent training mechanism, and took advantage of the geographical advantages of the Greater Bay Area. Establish in-depth cooperation with a number of clinical research institutions, scientific research institutions, testing institutions, review institutions and pharmaceutical companies in South China.
President Lu Peihua introduced that at present, the cell culture technology and clinical research services of Lu Daopei Medical Group are relatively mature, so we should give full play to our respective strengths, make good use of the advantages of cell culture technology of Lu Daopei Medical Group's Hubei stem cell bank, the advantages of Shenzhen Cell Valley's industrial production, and the advantages of cell therapy clinical research services of Lu Daopei Medical Group for differentiated development. Breakthrough was sought from the preparation technology, virus vector and other aspects.
The two sides expressed that they should take this exchange visit as a new opportunity to cooperate in the upper, middle and lower reaches to solve the technical barriers of the early work as soon as possible, carry out a number of new product development pipelines simultaneously, and promote the innovative research and development of new cell therapy products based on retroviral vector technology. Thus driving the domestic cell therapy industry technological innovation and rapid development.
After the meeting, under the guidance of President Lu Peihua, the Shenzhen Cell Valley team visited Beijing Ludaopei Hospital of Ludaopei Medical Group, and Professor Shi Yuanyuan, chairman of the board, highly praised the humanistic construction, environmental construction and image construction of Beijing Ludaopei Hospital.
Lu Daopei Medical Group is a private medical group founded by Academician Lu Daopei in 2012, which focuses on the treatment, scientific research and teaching of blood diseases and tumors. After more than ten years of unremitting efforts, it has developed into four medical institutions: Hebei Yanda Ludaopei Hospital, Beijing Ludaopei Hospital, Beijing Ludaopei Blood Disease Hospital, Shanghai Daopei Blood Disease Hospital (under preparation).
The hematopoietic stem cell Transplantation Department of Ludaopei Hospital is one of the most active transplantation centers in the world. The number of hematopoietic stem cell transplantation completed each year accounts for nearly 10% of the total number of transplants in China, and the number of refractory recurrent and salvagable hematopoietic stem cell transplantation cases completed each year ranks among the top in China, making the results of half-identical transplantation comparable to non-blood transplantation and sib transplantation. In 2021, there were 1168 transplant cases: 843 cases of semi-identical transplants, accounting for more than 72%; 167 cases of non-consanguineous transplantation; Total zygote transplantation in 128 cases; Non-blood umbilical cord blood transplantation in 10 cases; There were 18 cases of autologous transplantation.
